What are the benefits and risks of adding aspirin therapy to VKA therapy for patients with AF with stable coronary artery disease or peripheral arterial disease?
The benefits of adding aspirin therapy to VKA therapy for patients with AF with stable coronary artery disease or peripheral arterial disease are that it can reduce the risk of death, stroke, systemic embolism, intracranial hemorrhage, major extracranial hemorrhage, myocardial infarction, and vascular death. However, the risks associated with this combination therapy are that it can increase the risk of bleeding events. This should be taken into account when considering this combination therapy.